Get started
Emergent BioSolutions Inc.Emergent BioSolutions Inc.Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

EBS chart


Full chart

EBS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪637.75 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.00 USD
Net income (FY)
‪−760.50 M‬ USD
Revenue (FY)
‪1.05 B‬ USD
Shares float
‪51.91 M‬
Beta (1Y)
3.81

Employees


Employees (FY)
‪1.6 K‬
Change (1Y)
−900 −36.00%
Revenue / Employee (1Y)
‪655.81 K‬ USD
Net income / Employee (1Y)
‪−475.31 K‬ USD

About Emergent BioSolutions Inc.


Sector
Health Technology
CEO
Joseph C. Papa
Headquarters
Gaithersburg
Website
emergentbiosolutions.com
Founded
1998
FIGI
BBG000GW06J7
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

EBS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

EBS highest yielding bonds


EBS5025997
Emergent BioSolutions Inc. 3.875% 15-AUG-2028
Yield to maturity
10.11%
Maturity date
Aug 15, 2028
EBS5025998
Emergent BioSolutions Inc. 3.875% 15-AUG-2028
Yield to maturity
—
Maturity date
Aug 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of EBS is 11.77 USD — it has increased by 7.00% in the past 24 hours. Watch Emergent BioSolutions Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Emergent BioSolutions Inc. stocks are traded under the ticker EBS.
EBS stock has risen by 29.20% compared to the previous week, the month change is a 28.49% rise, over the last year Emergent BioSolutions Inc. has showed a 455.19% increase.
We've gathered analysts' opinions on Emergent BioSolutions Inc. future price: according to them, EBS price has a max estimate of 16.00 USD and a min estimate of 12.00 USD. Watch EBS chart and read a more detailed Emergent BioSolutions Inc. stock forecast: see what analysts think of Emergent BioSolutions Inc. and suggest that you do with its stocks.
EBS reached its all-time high on Aug 6, 2020 with the price of 137.61 USD, and its all-time low was 1.42 USD and was reached on Feb 6, 2024. View more price dynamics on EBS chart.
See other stocks reaching their highest and lowest prices.
EBS stock is 12.84% volatile and has beta coefficient of 3.81. Track Emergent BioSolutions Inc. stock price on the chart and check out the list of the most volatile stocks — is Emergent BioSolutions Inc. there?
Today Emergent BioSolutions Inc. has the market capitalization of ‪637.75 M‬, it has increased by 5.96% over the last week.
Yes, you can track Emergent BioSolutions Inc. financials in yearly and quarterly reports right on TradingView.
Emergent BioSolutions Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
EBS earnings for the last quarter are 1.37 USD per share, whereas the estimation was 0.10 USD resulting in a ‪1.23 K‬% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Emergent BioSolutions Inc. earnings.
Emergent BioSolutions Inc. revenue for the last quarter amounts to ‪293.80 M‬ USD, despite the estimated figure of ‪290.33 M‬ USD. In the next quarter, revenue is expected to reach ‪248.37 M‬ USD.
EBS net income for the last quarter is ‪114.80 M‬ USD, while the quarter before that showed ‪−283.10 M‬ USD of net income which accounts for 140.55% change. Track more Emergent BioSolutions Inc. financial stats to get the full picture.
No, EBS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has ‪1.60 K‬ employees. See our rating of the largest employees — is Emergent BioSolutions Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Emergent BioSolutions Inc. EBITDA is ‪25.40 M‬ USD, and current EBITDA margin is −4.09%. See more stats in Emergent BioSolutions Inc. financial statements.
Like other stocks, EBS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Emergent BioSolutions Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Emergent BioSolutions Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Emergent BioSolutions Inc. stock shows the neutral signal. See more of Emergent BioSolutions Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.